AIMS: To evaluate the different expression patterns and the prognostic significance of cell cycle regulatory molecules in diffuse large B-cell lymphomas (DLBCLs) of germinal centre (GC) and non-GC phenotypes. METHODS AND RESULTS: Tissue microarray slides composed of 126 extranodal and 88 nodal DLBCLs were immunostained for p16, p21, p27, p14 and p53. DLBCLs were classified into GC and non-GC phenotype according to the immunohistochemical expression of bcl-6, CD10, and MUM1. Aberrant expression of p53 was more frequent in the GC phenotype in nodal cases (P = 0.038), and the loss of p16, p21 and p14 expression was significantly more common in the non-GC phenotype (P = 0.004, P = 0.001, P < 0.001). Concurrent disruptions of the p16-Rb and p14-p53 pathways as represented by the immunoprofile of p16/p14/p53 (-/-/+) were associated with a poor prognosis in the GC phenotype [mean survival 31 months in the p16/p14/p53 (-/-/+) group versus 62 months in the other groups, P =0.0485]. CONCLUSIONS: The expression and prognostic implications of cell cycle regulatory molecules differ between GC and non-GC phenotypes in DLBCLs. The immunoprofile of p16/p14/p53 (-/-/+) within the GC phenotype of DLBCLs can be defined as a poor prognostic subgroup.
AIMS: To evaluate the different expression patterns and the prognostic significance of cell cycle regulatory molecules in diffuse large B-cell lymphomas (DLBCLs) of germinal centre (GC) and non-GC phenotypes. METHODS AND RESULTS: Tissue microarray slides composed of 126 extranodal and 88 nodal DLBCLs were immunostained for p16, p21, p27, p14 and p53. DLBCLs were classified into GC and non-GC phenotype according to the immunohistochemical expression of bcl-6, CD10, and MUM1. Aberrant expression of p53 was more frequent in the GC phenotype in nodal cases (P = 0.038), and the loss of p16, p21 and p14 expression was significantly more common in the non-GC phenotype (P = 0.004, P = 0.001, P < 0.001). Concurrent disruptions of the p16-Rb and p14-p53 pathways as represented by the immunoprofile of p16/p14/p53 (-/-/+) were associated with a poor prognosis in the GC phenotype [mean survival 31 months in the p16/p14/p53 (-/-/+) group versus 62 months in the other groups, P =0.0485]. CONCLUSIONS: The expression and prognostic implications of cell cycle regulatory molecules differ between GC and non-GC phenotypes in DLBCLs. The immunoprofile of p16/p14/p53 (-/-/+) within the GC phenotype of DLBCLs can be defined as a poor prognostic subgroup.
Authors: Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Xuan J Wang; Carlos E Bueso-Ramos; Guilin Tang; Sa Wang; Yasuhiro Oki; Parth Desai; Joseph D Khoury; Roberto N Miranda; Zhenya Tang; Nishitha Reddy; Shaoying Li Journal: Mod Pathol Date: 2016-10-14 Impact factor: 7.842
Authors: Elizabeth L Courville; Sophia Yohe; David Chou; Valentina Nardi; Aleksandr Lazaryan; Beenu Thakral; Andrew C Nelson; Judith A Ferry; Aliyah R Sohani Journal: Mod Pathol Date: 2016-07-22 Impact factor: 7.842
Authors: Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Upendra Hegde; Nicole Grant; Seth M Steinberg; Mark Raffeld; Martin Gutierrez; Bruce A Chabner; Louis Staudt; Elaine S Jaffe; John E Janik Journal: J Clin Oncol Date: 2008-03-31 Impact factor: 44.544
Authors: A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon Journal: Br J Cancer Date: 2006-11-21 Impact factor: 7.640
Authors: Charles H Lawrie; Jianxiang Chi; Stephen Taylor; Daniela Tramonti; Erica Ballabio; Stefano Palazzo; Nigel J Saunders; Francesco Pezzella; Jacqueline Boultwood; James S Wainscoat; Christian S R Hatton Journal: J Cell Mol Med Date: 2008-12-24 Impact factor: 5.310